Our data suggest that co-administration of SVP-Rapa may be an innovative and safe strategy to induce durable immune tolerance to rhGAA during the ERT in patients with Pompe disease, leading to improved clinical outcomes. The gene discussed is TRERF1; the disease is Glycogen storage disease due to acid maltase deficiency.